Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A Randomized Trial
| Autor: | Poordad, Fred, Lawitz, Eric, Reddy, K. Rajender, Afdhal, Nezam, Hézode, Christophe, Zeuzem, Stefan, Lee, Samuel, Calleja, Jose Luis, Brown, Robert, Craxi, Antonio, Wedemeyer, Heiner, Nyberg, L. M., Nelson, David, Rossaro, Lorenzo, Balart, Luis, Morgan, Timothy, Bacon, Bruce, Flamm, Steven, Kowdley, Kris, Deng, Weiping, Koury, Kenneth, Pedicone, Lisa, Dutko, Frank, Burroughs, Margaret, Alves, Katia, Wahl, Janice, Brass, Clifford, Albrecht, Janice, Sulkowski, Mark, Bailey, R., Cooper, C., Feinman, S.V., Marotta, P., Tam, E., Wong, F., Bourlière, Marc, Bronowicki, Jean-Pierre, Hezode, Christophe, Tran, A., Goeser, Tobias, Klass, D., Schmid, R., Pirisi, M., Zuin, M., Bennett, M., Bernstein, D., Box, T., Boyer, T., Clain, D., Crippin, J., Davis, M., Felizarta, Franco, Freilich, Bradley, Galati, Joseph, Galler, G., Ghalib, Reem, Gibas, A., Godofsky, E., Gordon, F., Gordon, S., Gross, J., Harrison, S., Herrera, J., Herrine, S., Herring, R., Jacobson, I., Joshi, S., Kilby, A., King, J., Koch, A., Kowdley, Kris V, Kwo, P., Lebovics, E., Lee, W., Levin, J., Li, Xiaojian, Luketic, Velimir, Mailliard, M., Mccone, Jonathan, Mikolich, D., Muir, A., Mullen, K., Nunes, F., Nyberg, A., Pandya, P., Pauly, M., Peine, C., Poleynard, Gary, Poulos, J., Pound, D., Rabinovitz, M., Ravendhran, Natarajan, Reddy, R., Reindollar, Robert, Reuben, A., Riley, T., Rubin, R., Russo, M., Ryan, M., Saab, S., Santoro, J., Schmidt, W., Sepe, T., Sherman, K., Sjögren, Marketa, Slim, J., Smith, C., Stein, L., Strauss, R., Vargas, H., Vierling, John, Witt, D., Wu, G., Younes, Z. |
|---|---|
| Přispěvatelé: | Texas Liver Institute [San Antonio], University of Texas Health Science Center, The University of Texas Health Science Center at Houston (UTHealth)- The University of Texas Health Science Center at Houston (UTHealth), Division of Gastroenterology (University of Pennsylvania), University of Pennsylvania [Philadelphia], Beth Israel Deaconess Medical Center, Harvard Medical School, Service d'hépato-gastro-entérologie [APHP Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Johann Wolfgang Goethe University Medical Center, University of Calgary, University Hospital Puerta de Hierro, Madrid, New York Presbyterian Hospital, Università degli studi di Palermo - University of Palermo, Department of Gastroenterology, Hepatology and Endocrinology (MHH), Hannover Medical School [Hannover] (MHH), Kaiser Permanente, University of Florida [Gainesville] (UF), University of California [Davis] (UC Davis), University of California (UC), Tulane University Health Sciences Center, Veterans Affairs Long Beach Healthcare System (VA Long Beach Healthcare System), Saint Louis University School of Medicine [St Louis], Feinberg School of Medicine, Northwestern University [Evanston], Virginia Mason Medical Center, Merck & Co. Inc, Johns Hopkins University School of Medicine [Baltimore], Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), University of California |
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Male
viruses [SDV]Life Sciences [q-bio] Hepacivirus medicine.disease_cause Gastroenterology Polyethylene Glycols law.invention chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial law Erythropoiesis Incidence Disease Management virus diseases Anemia Middle Aged Recombinant Proteins 3. Good health Treatment Outcome 030220 oncology & carcinogenesis Drug Therapy Combination Female 030211 gastroenterology & hepatology Algorithms medicine.drug medicine.medical_specialty Genotype Proline Side effect Hepatitis C virus Interferon alpha-2 Antiviral Agents 03 medical and health sciences Internal medicine Boceprevir Ribavirin medicine Humans Erythropoietin DAA Dose-Response Relationship Drug Hepatology business.industry Interferon-alpha Hepatitis C Chronic biochemical phenomena metabolism and nutrition medicine.disease digestive system diseases Side Effect Logistic Models chemistry Immunology Hemoglobin business EPO |
| Zdroj: | Gastroenterology Gastroenterology, 2013, 145 (5), pp.1035-1044.e5. ⟨10.1053/j.gastro.2013.07.051⟩ Gastroenterology, WB Saunders, 2013, 145 (5), pp.1035-1044.e5. ⟨10.1053/j.gastro.2013.07.051⟩ |
| ISSN: | 0016-5085 1528-0012 |
| Popis: | International audience; Background & AimsTreatment of hepatitis C virus (HCV) infection with boceprevir, peginterferon, and ribavirin can lead to anemia, which has been managed by reducing ribavirin dose and/or erythropoietin therapy. We assessed the effects of these anemia management strategies on rates of sustained virologic response (SVR) and safety.MethodsPatients (n = 687) received 4 weeks of peginterferon and ribavirin followed by 24 or 44 weeks of boceprevir (800 mg, 3 times each day) plus peginterferon and ribavirin. Patients who became anemic (levels of hemoglobin approximately ≤10 g/dL) during the study treatment period (n = 500) were assigned to groups that were managed by ribavirin dosage reduction (n = 249) or erythropoietin therapy (n = 251).ResultsRates of SVR were comparable between patients whose anemia was managed by ribavirin dosage reduction (71.5%) vs erythropoietin therapy (70.9%), regardless of the timing of the first intervention to manage anemia or the magnitude of ribavirin dosage reduction. There was a threshold for the effect on rate of SVR: patients who received |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|